** U.S.-listed shares of Oncolytics Biotech ONC.TO, ONCY.O rise 35.8% to $1.10 premarket
** ONCY says its pancreatic cancer therapy, pelareorep, has received regulatory approval to continue patient enrollment
** ONCY is evaluating pelareorep in combination with chemotherapy regimen Folfirinox and immunotherapy atezolizumab
** ONCY says it will move forward with full enrollment of 30 newly diagnosed pancreatic ductal adenocarcinoma (PDAC) patients in the first stage
** All 5 brokerages covering the stock rate it "buy"
** ONCY fell ~31% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。